Remission in Cushing’s disease is predicted by cortisol burden and its withdrawal following pituitary surgery

Aim To ascertain the predictors of remission and relapse in patients of Cushing’s disease (CD) undergoing pituitary transsphenoidal surgery (TSS). Methods Patients with CD subjected to TSS over 35 years at a tertiary care center were included. Patients were grouped into remission and persistent disease at 1 year after surgery, and were further followed up for relapse. Demographic, clinical, biochemical, histological, radiological and post-operative follow-up parameters were analyzed. Results Of the 152 patients of CD, 145 underwent TSS. Remission was achieved in 95 (65.5%) patients at 1 year. Patients in remission had shorter duration of symptoms prior to presentation ( p = 0.009), more frequent presence of proximal myopathy ( p = 0.038) and a tumor size of < 2.05 cm ( p = 0.016) in comparison to those with persistent disease. Post-TSS, immediate post-operative 0800-h cortisol (< 159.85 nmol/L; p = 0.001), histological confirmation of tumor ( p = 0.045), duration of glucocorticoid replacement (median 90 days; p = 0.001), non-visualization of tumor on MRI ( p = 0.003), new-onset hypogonadism ( p = 0.001), 3-month 0800-h cortisol (< 384.9 nmol/L; p = 0.001), resolution of diabetes ( p = 0.001) and hypertension ( p = 0.001), and recovery of hypothalamic–pituitary–adrenal axis ( p = 0.018) favored remission. In logistic regression model, requirement of glucocorticoid replacement ( p = 0.033), and resolution of hypertension post-TSS ( p = 0.003) predicted remission. None of the parameters could predict relapse. Conclusion The study could ascertain the predictors of remission in CD. Apart from the tumor characteristics, surgical aspects and low post-operative 0800-h cortisol, the results suggest that baseline clinical parameters, longer glucocorticoid replacement, and resolution of metabolic complications post-TSS predict remission in CD. Long-term follow-up is essential to look for relapse.